Skip Navigation

A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT03323151

Study #:
STUDY00145312

Start Date:
May 31, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03323151

View Complete Trial Details & Eligibility at ClinicalTrials.gov